China’s Personalized mRNA Cancer Vaccine Race Accelerates After Moderna and Merck’s Phase 3 Melanoma Success
The personalized cancer vaccine field has reached a major inflection point. Moderna and Merck announced on August 19, 2026 that their Phase 3 INTerpath-001 trial of intismeran autogene (V940/mRNA-4157) plus KEYTRUDA (pembrolizumab) met both its primary…
Merck and InventisBio Ink a Partnership to Advance Clinical Development of Small-Molecule Cancer Drugs
August 10, 2026, Merck R&D (China) Co., Ltd. and InventisBio Co., Ltd. (or InventisBio), an innovative pharmaceutical company listed on the Science and Technology Innovation Board, simultaneously announced that they had signed a cooperation agreement…